4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA ...

By now, your news feed, your dinner table conversations, and your doctor’s office have been flooded with chatter about the ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

BOWLING GREEN, Ohio — The final phase of Bowling Green’s South Main Street improvement ... Beginning the week of Nov. 3, ...

Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...

Tiziana Life Sciences is a buy due to its platform optionality and upcoming catalysts that outweigh its dilution risk and ...

Leaders in Durham are working on a new approach to reduce gun violence. During a joint meeting, elected officials discussed ...

The latest helmets to meet those standards are the Acerbis Airstrike and Airoh Aviator 3 Evo, both of which are off-road lids ...

XRP has continued to play a role in global digital payment systems in 2025. Originally designed as a token for cross-border settlement, it is now recognized as a bridge asset that is being adopted by ...

Now, it’s worth noting Stock Advisor’s total average return is 1,071% — a market-crushing outperformance compared to 196 % ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.